COX-2 Inhibitor/Aspirin GI Safety Study Suggested By FDA Advisory Cmte.

Additional research is needed on the gastrointestinal safety of concomitant COX-2 inhibitor and aspirin use, FDA's Arthritis Advisory Committee recommended during its Feb. 7-8 review of sNDAs for Pharmacia/Pfizer's Celebrex and Merck's Vioxx.